ABT – abbott laboratories (US:NYSE)

Blood Screening Market Research | 2023-2030 [MarketWatch]

Biotech Networks Extends its Reach to Twelve US Life Science Hubs and Announces 2023-2024 Scientific Speed Networking Event Tour

Abbott accuses one of its former scientists of trade-secrets theft in US court [Reuters]

Abbott, Real Madrid and the Real Madrid Foundation Band Together to 'Beat Malnutrition' Globally Through New Campaign

Abbott Laboratories (NYSE: ABT) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating. They now have a $112.00 price target on the stock.

Immunoassay Instruments Market Research | 2023-2030 [MarketWatch]

Abbott Laboratories: Organic Growth Will Carry It Through [Seeking Alpha]

2030, Pediatric Epilepsy Therapeutics Market: Trend & Outlook [MarketWatch]

FTC investigates America's baby formula shortages [CNN]

Spring 2023 Layoff Tracker: Meta, First Citizens Bank Axe Hundreds Of Jobs [Forbes]

Feds probe whether baby formula makers broke the law in bidding for state contracts [CBS News]

Abbott, other baby formula makers face FTC investigation for potential collusion [Financial Post (Toronto, Ontario, Canada)]

Abbott, other baby formula makers face FTC investigation for potential collusion [Reuters]

European Study Finds the Abbott CardioMEMS Sensor Results in Improved Quality of Life and 44% Reduction in Heart Failure Hospitalizations

Wall Street Breakfast Podcast: America's AI Strategy [Seeking Alpha]

Abbott, other baby-formula makers see FTC probe over collusion - report [Seeking Alpha]

FTC probing baby-formula makers for collusion: report [FOX Business Network]

Abbott, other formula makers face FTC investigation for collusion - WSJ [Reuters]

Abbott, other formula makers face FTC investigation for collusion - WSJ [Reuters]

Abbott recalled baby formula claims tossed by federal judge [Seeking Alpha]

2030, Epilepsy Therapeutics Market: Growth & Statistics [MarketWatch]

Judge tosses some claims in Abbott baby formula litigation [Reuters]

Abbott Unveils Late-Breaking Data Showing the World's First Dual-Chamber Leadless Pacemaker Study Met All Three Primary Endpoints

Abbott Receives FDA Approval for TactiFlex™ Ablation Catheter for Treatment of Abnormal Heart Rhythm

Abbott's India arm posts 9.5% rise in fourth-quarter profit [Reuters]